Coronado Biosciences is a biopharmaceutical company engaged in developing novel immunotherapy biologic agents for treating autoimmune diseases and cancer. The company’s two chief pharmaceutical product candidates in clinical development are: TSO (Trichuris suis ova or CNDO-201), which is a biologic for treating autoimmune diseases; and CNDO-109, which is a biologic that activates natural killer (NK) cells for treating acute myeloid leukemia, multiple myeloma and solid tumors. For more information, visit the company’s Web site: http://www.coronadobiosciences.com
Let us hear your thoughts below: